Essential Pharma Partners with AGC Biologics for Immunotherapy Production in High-Risk Neuroblastoma Treatment
Wednesday, June 12, 2024
Essential Pharma, a global specialty pharmaceutical company, has formed a strategic alliance with AGC Biologics, a leading contract development and manufacturing organization in the biopharmaceutical sector. AGC Biologics will be tasked with producing Hu1418K322A (Hu14.18), a humanized monoclonal antibody developed by Essential Pharma for treating high-risk neuroblastoma.
This partnership will involve AGC Biologics in process development, scaling, and manufacturing as Essential Pharma prepares to initiate clinical trials and interact with regulatory bodies in the near future.
Essential Pharma’s rare disease division, stated, "This partnership is a significant step forward in developing Hu14.18 and bringing it to market. Establishing an inventory of Hu14.18 is an exciting opportunity. We are entering a phase of intensive regulatory engagement, which will coincide with the final stages of clinical development. This advancement brings us closer to offering this promising treatment to patients in dire need of better options."
Essential Pharma, commented, "AGC Biologics' expertise in antibody development and manufacturing is crucial for accelerating the late-stage development of Hu14.18, which holds significant potential for young children with high-risk neuroblastoma. We are eager to work closely with AGC to deliver this potentially transformative therapy to the patients who need it."
AGC Biologics, added, "We are excited that Essential Pharma has chosen us to manufacture this innovative therapy. Our facility in Copenhagen has the necessary expertise and experience to support the late-stage development and production of Hu14.18. We look forward to collaborating with Essential Pharma to ensure that the product meets the high standards required for clinical trials and regulatory submissions, enabling us to provide this life-saving treatment to patients globally."
After acquiring Renaissance Pharma in April 2024, Essential Pharma has taken on the responsibility for developing Hu14.18. A Phase II trial has shown positive outcomes, integrating Hu14.18 into both first-line and post-consolidation therapy for HRNB patients, achieving a 3-year event-free survival rate of 73.7% and an overall survival rate of 86.0%. These findings, published in the Journal of Clinical Oncology in December 2021, are approaching a five-year overall survival milestone.
Source: globenewswire.com
